Compare Sirius XM Holdings Inc (SIRI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs TG Therapeutics Inc — how do they compare? Sirius XM Holdings Inc trades at $28.39 (market cap $9.70B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Sirius XM Holdings Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SIRI | TGTX | |
|---|---|---|
Market Cap | $9.70B | $7.64B |
Sector | Media | Health |
52-Week High | $32.59 | $59.06 |
52-Week Low | $19.92 | $26.94 |
Enterprise Value | $18.98B | $7.84B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings (SIRI) trades at $28.40, down 1.32% with bearish technical signals despite attractive valuation metrics including P/E of 11.56 and P/B of 0.81. The company reported mixed Q2 2026 results with a revenue beat but earnings miss, while maintaining stable cash flow and announcing a $0.27 dividend. Recent news highlights satellite communications growth potential and institutional positioning.
SIRI presents a value opportunity with strong cash generation and dividend yield, though near-term headwinds include subscriber challenges and debt levels. Analyst consensus remains bullish with $33.17 price target representing 17% upside, but investors should monitor execution on subscriber retention and competitive pressures in the evolving audio streaming landscape.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
